Why the study?
Post-thrombotic syndrome frequently follows deep vein thrombosis but is challenging to predict and prevent, making identification of high-risk patients important for targeting preventative strategies.
Does the overall hemostatic potential assay predict the development of post-thrombotic syndrome in anticoagulated patients following deep vein thrombosis?
Does the overall hemostatic potential assay predict the development of post-thrombotic syndrome in anticoagulated patients following deep vein thrombosis?
The overall hemostatic potential assay, performed while patients are still anticoagulated, may help identify those at high risk of developing post-thrombotic syndrome after deep vein thrombosis.
Answers are grounded in this paper and cite their sources.
OHP assay during anticoagulation may identify higher PTS risk after DVT; hypothesis-generating pilot data requiring prospective validation before any practice change.
Deep vein thrombosis (DVT) frequently leads to post-thrombotic syndrome (PTS) which is challenging to predict and prevent. Identifying those at high risk of developing PTS may help to focus preventative strategies. Adults were recruited within 3 months of DVT diagnosis. Blood was sampled during the therapeutic anticoagulation phase. Overall hemostatic potential (OHP) assay, a spectrophotometric assay, was performed on platelet-poor plasma (PPP). In this assay, fibrin formation is triggered by small amounts of thrombin and termed the overall coagulation potential (OCP). Simultaneously, thrombin and tissue plasminogen activator are added to PPP and the resulting fibrin aggregation curve is the overall hemostatic potential (OHP). Fibrinolysis is expressed by the parameter overall fibrinolytic potential (OFP%). Patients were followed up at regular intervals. PTS was diagnosed if the Villalta score was ≥5 at least 3 months after the DVT diagnosis. Results were obtained from 190 patients (53.7% male, mean age 56.9 years). PTS developed in 62 (32.6%) patients. Patients with PTS displayed significantly higher median OCP (45.8 vs. 38.8 units, p = 0.010), OHP (12.8 vs. 9.2 units, p = 0.005) and significantly lower OFP (74.1 vs. 75.6%, p = 0.050). PTS patients had higher neutrophil/lymphocyte ratios (NLR) (2.3 vs. 1.9, p = 0.007). After multivariate analysis, proximal DVT location, history of varicose veins, NLR ≥ 2.6, OHP > 13.0 units and weight >108 kg were independent predictors for PTS. The c-statistic of the multivariate model was 0.77. This pilot study suggests that OHP testing while patients are still anticoagulated may assist in the prediction of PTS development and could assist in prognostication and targeting of preventative measures. However, larger prospective studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
McLeod et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: